The decision comes in the wake of the company’s updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.
The pharmaceutical industry is undergoing a significant transformation in how companies approach their commercial operations. Over the next five years, we expect to see large pharma outsourcing more than 50 percent of their commercial activities. This shift is driven by several key factors that are reshaping the industry landscape.
The drug was generally safe and well tolerated at all doses tested in the study, Neurocrine said, adding that it plans to begin late-stage trials early next year.
The vaccine maker is competing with well-established rivals in markets that have a mix of demand issues as well as commercial and structural headwinds, as the biotech looks to establish new growth drivers.
“Citrus helps clients navigate the pathway from molecule to medicine, solving the challenges at each decision point, derisking launch success, and bringing a range of services to our clients at their time of need,” stated CEO Neil Matheson. “Lisa has more than 15 years’ experience communicating the value of medicines to all stakeholders, ultimately resulting in patient access and improved outcomes, and I am excited to work with Lisa to continue to build this critical part of our comprehensive service offering under the Citrus Engage banner.”
The company announced Tuesday that despite the error preventing the analysis of late-stage results, the FDA confirmed that data from other completed trials are sufficient to support an NDA submission in the first quarter of 2025.